Cytek Biosciences, Inc. CTKB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$18.87M+57.2% | -$44.08M-705% | -$5.48M+1.9% | -$5.58M+51.0% | -$11.4M— | ||
| $1.87M-1.6% | $1.9M-1.1% | $1.92M+1.5% | $1.89M+0.8% | $1.88M+1.1% | ||
| $4.86M-12.0% | $5.53M-2.0% | $5.64M-17.0% | $6.79M+2.4% | $6.63M-5.3% | ||
| -$183K-100% | $38.58M+1,568% | -$2.63M-27.8% | -$2.06M-512% | -$336K+88.4% | ||
| -$55K+8.3% | -$60K+41.2% | -$102K+32.9% | -$152K-50.5% | -$101K-3,267% | ||
| $459K+47.6% | $311K+522% | $50K-3.8% | $52K— | $0— | ||
| -$9.65M— | —— | —— | -$652K+89.9% | -$6.45M-169% | ||
| $1.63M— | —— | $2.22M-37.8% | $3.57M+138% | $1.5M+175% | ||
| $390K— | —— | $588K-22.5% | $759K+85.1% | $410K+58.9% | ||
| -$3.89M-183% | $4.71M+434% | -$1.41M-150% | $2.79M+232% | -$2.12M— | ||
| -$3.85M-215% | $3.35M+401% | -$1.11M-513% | $270K+81.2% | $149K-79.9% | ||
| -$236K— | —— | —— | —— | $0— | ||
| $1.18M-32.3% | $1.74M+511% | $284K+19.3% | $238K-82.3% | $1.34M-3.6% | ||
| $948K-17.3% | $1.15M+0.4% | $1.14M+4.0% | $1.1M+8.8% | $1.01M+13.8% | ||
| -$159K— | —— | -$1.08M+7.1% | -$1.16M-12.3% | -$1.04M— | ||
| -$2.74M-255% | -$771K+80.2% | -$3.9M— | $0+100% | -$125K-106% | ||
| $2.17M+117% | $1M+52.4% | $657K-58.3% | $1.58M+85.7% | $849K-5.0% | ||
| $33K+3.1% | $32K— | $0-100% | $74K+3,600% | $2K-77.8% | ||
| $6K-96.9% | $195K+19,400% | $1K-95.7% | $23K-30.3% | $33K-82.7% | ||
| -$27.08M— | —— | $18.92M+215% | -$16.41M-274% | $9.45M+115% | ||
| $0— | —— | —— | $4.51M-57.6% | $10.63M+51.8% | ||
| $5.07M+258% | $1.42M-32.3% | $2.09M+51.0% | $1.39M+101% | $690K-75.2% | ||
| $869K-70.4% | $2.94M+1,928% | $145K+2.1% | $142K-90.6% | $1.52M+992% | ||
| $21K-75.3% | $85K-38.0% | $137K+114% | $64K+64.1% | $39K-71.7% | ||
| $3.98M+425% | -$1.23M— | —— | -$2.6M+77.5% | -$11.55M-217% | ||
| $646K-54.2% | $1.41M+66.9% | $846K+192% | -$921K+25.0% | -$1.23M-181% | ||
| -$25.19M-938% | -$2.43M— | —— | -$19.83M-475% | -$3.45M+94.6% | ||
| -$3.75M-276% | $2.13M— | $0-100% | $25K— | $0-100% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.18M-32.3% | $1.74M+511% | $284K+19.3% | $238K-82.3% | $1.34M-3.6% | ||
| -$389K-32.8% | -$293K-16.3% | -$252K-13.0% | -$223K+38.9% | -$365K+67.3% | ||
| -$159K— | —— | -$1.08M+7.1% | -$1.16M-12.3% | -$1.04M— | ||
| -$3.85M-215% | $3.35M+401% | -$1.11M-513% | $270K+81.2% | $149K-79.9% | ||
| -$47K+93.8% | -$761K-640% | $141K-2.1% | $144K-2.7% | $148K+102% | ||
| $193K-84.4% | $1.24M+836% | $132K+529% | $21K-93.3% | $314K+17.2% | ||
| -$1.26M— | —— | —— | -$1.62M-8.2% | -$1.49M+5.5% | ||
| $948K-17.3% | $1.15M+0.4% | $1.14M+4.0% | $1.1M+8.8% | $1.01M+13.8% | ||
| -$236K— | —— | —— | —— | $0— | ||
| $459K+47.6% | $311K+522% | $50K-3.8% | $52K— | $0— | ||
| $33K+3.1% | $32K— | $0-100% | $74K+3,600% | $2K-77.8% | ||
| $6K-96.9% | $195K+19,400% | $1K-95.7% | $23K-30.3% | $33K-82.7% | ||
| $239K-10.8% | $268K+56.7% | $171K+67.6% | $102K-20.9% | $129K-0.8% | ||
| $869K-70.4% | $2.94M+1,928% | $145K+2.1% | $142K-90.6% | $1.52M+992% | ||
| $1.31M+2,873% | $44K-2.2% | $45K— | —— | $234K+200% | ||
| -$159K— | —— | -$1.08M+7.1% | -$1.16M-12.3% | -$1.04M— | ||
| $3K-80.0% | $15K— | —— | —— | $47K— | ||
| $0-100% | $1.09M— | —— | $7.43M+1,141% | $599K-44.5% | ||
| -$3.75M-276% | $2.13M— | $0-100% | $25K— | $0-100% | ||
| $180K— | —— | —— | —— | $0— | ||
| -$4.9M-177% | -$1.77M+61.1% | -$4.56M-210% | -$1.47M-50.8% | -$974K-188% | ||
| -$4.9M-177% | -$1.77M+61.1% | -$4.56M-210% | -$1.47M-50.8% | -$974K-188% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytek Biosciences, Inc. generate?
- Cytek Biosciences, Inc. (CTKB) generated -$7.4M in operating cash flow over the trailing twelve months.
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $5.4M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.7M over the trailing twelve months, down 172.6% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
